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Masked hypertension in obesity: potential predictors and
arterial damage
Isabel E. Kennya, Sahrai Saeeda,b, Eva Gerdtsa, Helga Midtbøa,b,
Hilde Hallanda and Mai T. Lønnebakkena
Background Masked hypertension (MHT), defined as
normal office blood pressure (BP) but high ambulatory BP,
has been associated with increased cardiovascular risk.
Although MHT has been associated with obesity, there is
limited knowledge on the prevalence and covariates of MHT
in obese cohorts.
Methods Office and ambulatory BP recordings and other
cardiovascular risk factors were assessed in 323 obese
participants included in the fat-associated cardiovascular
dysfunction study (mean age 48.9± 9.0 years, 55% women,
mean BMI 32.3 ± 4.4 kg/m2). Office BP 130–139/
85–89mmHg was considered high-normal. Subclinical
arterial damage was identified as carotid–femoral pulse
wave velocity more than 10m/s by applanation tonometry
or carotid plaque by ultrasound (maximal intima–media
thickness ≥ 1.5mm).
Results MHT was present in 17.1% of the population.
Patients with MHT had a higher prevalence of metabolic
syndrome, high-normal office BP, and were more often male
compared with the normotensive (NT) individuals (all
P< 0.05), but were younger and had lower prevalence of
diabetes and subclinical arterial damage than the sustained
hypertensive group (all P< 0.05). In multinomial logistic
regression analysis, MHTwas associated with the presence
of metabolic syndrome and high-normal office BP
compared with NT individuals, and lower pulse wave
velocity and fewer carotid plaques than sustained
hypertension (all P< 0.05).
Conclusion In obese patients, MHT was associated with
the presence of metabolic syndrome and high-normal office
BP compared with NT individuals, but less subclinical
arterial damage than sustained hypertensive
patients. Blood Press Monit 22:12–17 Copyright © 2017
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Patients with masked hypertension (MHT) have been
shown to carry a double risk of cardiovascular events com-
pared with normotensive (NT) individuals, comparable to
that of patients with sustained hypertension (SHT) [1–3].
MHT has been associated with target organ damage in the
heart, arteries, kidney, and brain in previous reports [3–9].
Several cardiovascular risk factors such as obesity, male sex,
exercise-induced hypertension, smoking, diabetes, and
family history of cardiovascular disease have also been found
to cluster in MHT [3]. Obesity is associated with metabolic
changes, which may involve glucose and lipid metabolism,
the fibrinolytic system, the autonomic nervous system, and
the endothelial function [10]. These changes all promote
cardiovascular inflammation and the development of cardi-
ovascular structural and functional changes [11]. From this, a
higher prevalence of MHT could be expected in obesity.
However, few studies have reported on the prevalence and
covariates of MHT within obese cohorts. This was the aim
of the present study.
Methods
Study population
The fat-associated cardiovascular dysfunction (FATCOR)
study has been on-going since 2009 aiming at identifying
determinants of subclinical target organ damage in obese
patients without known cardiovascular disease [12,13].
The FATCOR study is a collaboration between a general
practitioner center specializing in the management of
obese patients, Alfahelse AS, and Department of Heart
Disease, Haukeland University Hospital, both situated in
Bergen, Norway. Inclusion criterion for the study was a
BMI more than 27.0 kg/m2 in healthy individuals aged
30–65 years. Exclusion criteria were previous myocardial
infarction, gastrointestinal disorders (including previous
gastric bypass or sleeve operations), severe psychiatric
illness, or inability to understand Norwegian language
[12]. For the present analysis, all individuals who had
measurements of both office blood pressure (BP) and
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ambulatory BP were included, a total of 339 participants.
The FATCOR study was approved by the Regional
Ethics Committee. All participants signed written
informed consent according to the declaration of Helsinki.
Blood pressure measurements
A standardized clinical examination by the general practi-
tioner at Alfahelse AS included the measurement of office BP
following the European Society of Hypertension guidelines
[14] using a validated digital automatic Omron M4 sphyg-
momanometer (Omron Healthcare Co., Ltd, Hoofddorp, the
Netherlands) and appropriate cuff size in relation to arm cir-
cumference. BP was measured three times at 1-min intervals
after patients had rested in the seated position for at least
5min. Office BP was taken as the average of the two last
measurements in the individual patient. High office BP was
defined as systolic BP greater than or equal to 140mmHg
and/or diastolic BP greater than or equal to 90mmHg. High-
normal office BP was defined as systolic BP 130–139mmHg
and/or diastolic BP 85–89mmHg.
24-H ambulatory BP recording was performed using a
noninvasive monitor (Diasys Integra II; Novacor, Cedex,
France) set to auscultatory mode. An appropriately sized
cuff for the nondominant arm was used, and the partici-
pants were instructed to relax their arm when the mea-
surement was initiated. BP was measured every 20 min
during daytime and every 30 min during night-time,
yielding an average of 78 measurements per 24 h. The
recording was repeated if less than 70% of the measure-
ments were technically valid. High 24-h BP was defined
as average 24-h systolic BP greater than or equal to
130 mmHg and/or average diastolic BP greater than or
equal to 80mmHg [14].
Study participants were grouped into BP categories
combining office and ambulatory BP measurements.
Participants were classified as NT when both office BP
and ambulatory BP were normal and SHT if both were
high. Participants with high office BP but normal ambu-
latory BP were classified as having white-coat hyperten-
sion (WCHT). The MHT participants had normal office
BP but high ambulatory BP. All participants using BP
medication were categorized as having SHT independent
of the actual BP measurements, even though WCHT
theoretically could be present in some of these treated
participants.
Cardiovascular risk factors
A standardized questionnaire was used to gather self-
reported information on the participants’ demographic
and socioeconomic characteristics, and medical history
including current use of medication and cardiovascular
risk factors. The information was quality assured by the
general practitioner. Fasting venous blood samples were
obtained to measure serum lipids, fasting glucose, and
serum creatinine. In nondiabetic patients, an oral glucose
tolerance test was performed. Urine albumin–creatinine
ratio was measured in a spot morning urine sample and
defined as high as 3.4 mg/mmol [14].
Obesity was identified as BMI of at least 30 kg/m2
according to the guidelines by the WHO [15]. Metabolic
syndrome was diagnosed if at least three of the following
features were present: (a) waist circumference of at least
88 cm in women and at least 102 cm in men, (b) office BP
of at least 130/85 mmHg or antihypertensive treatment,
(c) fasting serum glucose of at least 5.6 mmol/l or blood
sugar lowering treatment, (d) fasting serum triglycerides
of at least 1.7 mmol/l, and (e) fasting serum high-density-
lipoprotein cholesterol less than 1.3 mmol/l in women
and less than 1.03 mmol/l in men in accordance with the
American Heart Association/National Heart, Lung and
Blood Institute guidelines [16].
Diabetes mellitus was defined as a history of diabetes,
use of antidiabetic medication, fasting glucose of at least
7.0 mmol/l, or postload plasma glucose after 2 h of more
than 11.0 mmol/l. Impaired glucose tolerance was
defined as serum glucose 7.8–11.0 mmol/l 2 h after oral
intake of 75 g of glucose. Impaired fasting glucose was
defined as fasting glucose of at least 6.1 mmol/l and less
than 7.0 mmol/l. Insulin resistance was determined from
homeostatic model assessment (HOMA-IR) [17].
Subclinical arterial damage
Carotid ultrasound was performed using a Phillips iE33
ultrasound machine (Phillips Healthcare, Best, the
Netherlands) and an 11–3MHz linear array transducer.
Maximal carotid intima–media thickness (cIMT) was mea-
sured in B-mode on both the far and the near wall in the
common carotid artery, carotid bulb, and internal carotid
artery on both sides. A carotid plaque was defined as focal
maximal cIMT greater than or equal to 1.5mm [18].
Carotid–femoral pulse wave velocity (PWV) was mea-
sured using applanation tonometry (SphygmoCor; AtCor
Medical, Sydney, West Ryde, Australia) according to
guidelines [19]. Pressure pulse waveforms were obtained
transcutaneously from the right common carotid and
femoral arteries with simultaneous recording of the elec-
trocardiogram for synchronizing carotid and femoral pulse
wave times as described previously [20]. The proximal
distance between the carotid site and the sternal notch
and distal distance between the sternal notch and the
femoral site were measured precisely. To find PWV, the
proximal distance was subtracted from the distal distance
and the net distance was divided by the transit time
between the two recording sites determined in relation to
the R wave on the ECG. PWV more than 10m/s was
defined as arterial organ damage [21], reflecting increased
arterial stiffness.
Statistics
Data management and statistical analysis was carried out
using SPSS, version 22 statistical software (IBM SPSS
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Statistics, Chicago, Illinois, USA). The study population
was divided into BP categories: NT, MHT, and SHT.
Continuous variables are presented as mean ± SD,
whereas categorical variables are presented as percen-
tages. The MHT group was compared with NT and
SHT groups using the χ2-test for categorical values and
analysis of variance for continuous variables with
Scheffe’s post-hoc test. Univariable covariables of MHT
were identified by logistic regression analyses within
groups of participants with normal office BP (NT and
MHT) and with elevated 24 h ambulatory BP (MHT and
SHT). Multinomial logistic regression analysis using an
MHT participant as a reference was used to identify
independent covariables of MHT. The results were
reported as odds ratio and 95% confidence intervals. A
P-value up to 0.05 was considered statistically significant
in all analyses.
Results
The prevalence of MHT was 17.1% in the total study
population. Only 16 (4.7%) participants had WCHT, and
this BP category was therefore excluded from further
analysis. Among participants with normal office BP (NT
and MHT groups), the prevalence of MHT was 39.2%.
Within the MHT group five (9%), participants had 24-h
systolic BP greater than or equal to 130 mmHg, 41 (71%)
participants 24-h diastolic BP had greater than or equal to
80mmHg, and 12 (21%) participants had both 24-h sys-
tolic BP greater than or equal to 130 mmHg and 24-h
diastolic BP greater than or equal to 80 mmHg.
Compared with the NT group, the MHT group had
higher prevalences of men, metabolic syndrome, and
high-normal office BP (Tables 1 and 2). Furthermore,
compared with NT patients, PWV was higher among
patients with MHT whereas carotid IMT and the pre-
valence of carotid plaque did not differ (Table 1 and
Fig. 1). The MHT group had a higher fasting C-peptide
than the NT group, although fasting serum glucose did
not differ (Table 3). Compared with patients with SHT,
patients with MHT were younger and had lower pre-
valences of metabolic syndrome, diabetes, and lower
glucosylated hemoglobin A1c (Tables 1 and 3), as well as
lower prevalences of arterial organ damage measured by
high PWV, increased cIMT, and carotid plaque (Fig. 1).
Covariables of masked hypertension
In univariable logistic regression analyses including NT
and MHT patients, male sex, presence of metabolic
syndrome, high-normal office BP, and high PWV were
associated with a higher risk for the presence of MHT (all
P< 0.05) (Table 4). In univariable logistic regression
analyses including MHT and SHT patients, MHT was
associated with younger age, lower prevalence of meta-
bolic syndrome and diabetes, and lower serum hemoglo-
bin A1c and fasting glucose, as well as lower prevalence of
established arterial damage measured by high PWV and
carotid plaque (all P< 0.05) (Table 4). In multinomial
logistic regression analysis, MHT was associated with the
presence of metabolic syndrome and high-normal office
BP (both P< 0.05) compared with NT, independent of
sex, diabetes, PWV, and carotid plaque (Table 5).
Compared with patients with SHT, MHT was associated
Table 1 Clinical characteristics in groups with normotensive,
masked hypertension, and sustained hypertensive
Variables NT (n=90) MHT (n=58) SHT (n=175)
Age (mean ± years) 45.7 ±9.2 44.9 ±7.8† 52.2 ± 8.2
Male (%) 33.3 55.2* 45.7
Hip circumference (cm) 114.8 ±13.3 115.4 ±8.2 115.3 ± 11.8
Waist circumference (cm) 105.5 ±11.0 109.5 ±9.2 110.0 ± 11.8
Height (cm) 172.0 ±9.6 174.2 ±8.0 171.6 ± 16.2
Weight (kg) 92.4 ±15.9 98.3 ±14.8* 97.3 ± 17.1
BMI (kg/m2) 31.1 ±3.9 32.2 ±4.0 32.6 ± 4.4
Obesity (%) 61.3 78.0 78.7
Fat mass (%) 37.2 ±7.9 35.7 ±8.8 37.3 ± 7.9
Muscle mass (kg) 55.2 ±12.2 58.7 ±13.9 58.1 ± 11.9
Use of antihypertensive drugs
(%)
0 0 47.6
Physical activity (h/week) 3.5 ±2.1 3.6 ±2.2 3.7 ± 2.9
Diabetes (%) 8.0 12.3† 29.3
Metabolic syndrome (%) 21.6 50.9* 67.3
Current smoker (%) 21.7 9.1 11.7
Family history of cardiovascular
events (%)
39.8 28.3 38.6
Known atrial fibrillation (%) 10.8 2.4 8.6
PWV (m/s) 6.8 ±1.1 7.5 ±1.3† 8.2 ± 1.9
Maximum carotid IMT (mm) 1.04 ±0.97 0.91 ±0.32† 1.24 ± 0.57
Mean carotid IMT (mm) 0.69 ±0.15 0.70 ±0.12† 0.84 ± 0.20
IMT, intima–media thickness; MHT, masked hypertension; NT, normotension;
PWV, pulse wave velocity; SHT, sustained hypertension.
*P<0.05 versus NT.
†P<0.05 versus SHT.
Table 2 Office and ambulatory blood pressure in groups with
normotension, masked hypertension, and sustained hypertension
Variables NT (n=90) MHT (n=58) SHT (n=175)
Office BP
Systolic BP (mmHg) 118.4 ±12.0 126.0 ±8.5*† 140.1 ±15.6
Diastolic BP (mmHg) 76.3 ±6.5 80.9 ±5.7*† 88.6 ±8.9
Office HR 66.4 ±8.5 67.5 ±8.4† 71.3 ±11.3
High-normal office BP (%) 23.3 47.4* 44.1







24-H systolic BP (mmHg) 112.8 ±8.7 124.7 ±9.2* 126.6 ±12.5
24-H diastolic BP (mmHg) 72.4 ±4.5 82.6 ±5.0* 81.2 ±8.5
24-H pulse pressure (mmHg) 40.5 ±7.9 42.1 ±9.0† 45.3 ±9.7
24-H HR (beats/min) 74.7 ±9.5 76.8 ±8.0 74.9 ±8.4
Daytime systolic BP (mmHg) 116.2 ±9.1 128.4 ±10.0* 130.3 ±13.1
Daytime diastolic BP (mmHg) 74.5 ±4.8 84.9 ±5.3* 83.6 ±8.5
Daytime pulse pressure
(mmHg)
41.6 ±8.2 43.5 ±9.1† 46.5 ±9.9
Daytime HR (beat/min) 77.3 ±10.1 79.7 ±8.4 77.0 ±8.9
Night-time systolic BP
(mmHg)
100.2 ±9.0 109.8 ±10.5* 113.1 ±14.1
Night-time diastolic BP
(mmHg)
64.4 ±5.9 73.3 ±6.9* 72.4 ±9.6
Night-time pulse pressure
(mmHg)
35.8 ±8.4 36.7 ±10.8† 40.9 ±11.2
Night-time HR (beats/min) 64.6 ±9.0 65.0 ±8.0 66.1 ±8.3
BP, blood pressure; HR, heart rate; MHT, masked hypertension; NT, normoten-
sion; SHT, sustained hypertension.
*P<0.05 versus NT.
†P<0.05 versus SHT.
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with lower PWV and lower prevalence of carotid plaque
(both P< 0.05) when adjusted for sex, diabetes, metabolic
syndrome, and presence of high-normal office BP
(Table 5).
Discussion
The present study in overweight and obese patients
without known cardiovascular disease shows that MHT
was common, found in 17.1% in the overall study
population and in 39.2% among patients with normal
office BP. Compared with NT patients, MHT was par-
ticularly associated with the presence of the metabolic
syndrome and high-normal office BP. Compared with
SHT patients, MHT patients had less established
atherosclerosis identified from high aortic stiffness
(PWV> 10m/s) or the presence of carotid plaque.
Previous studies have reported varying prevalences of
MHT: from 8.5 to 17% in general populations [1,22]. The
present study found a prevalence of MHT comparable to
the upper range of that reported from general populations
[3]. Treatment of hypertension is documented to effec-
tively reduce subclinical target organ damage and asso-
ciated cardiovascular event risk [23]. The higher
prevalence of subclinical arterial damage reported pre-
viously in MHT patients in some studies is probably
related to the delayed diagnosis of hypertension in these
patients [24]. Other studies have also shown the association
of high-normal office BP with MHT [3,25], suggesting that
MHT may represent a missed diagnosis of hypertension
because of normal fluctuations in office BP. A longitudinal
study of Norwegian men with high-normal office BP at
screening for military service showed increased incidence
of MHT in these patients when re-examined 17 years later
[26], in line with our findings.
MHT has been associated with clustering of cardiovas-






























Prevalences of subclinical arterial disease in masked hypertension
(MHT) compared with normotensive (NT) and sustained hypertensive
(SHT) groups. PWV, pulse wave velocity; UACR, urine
albumin–creatinine ratio.
Table 3 Biochemical characteristics in groups with normotension,
masked hypertension, and sustained hypertension
Variables NT (n=90) MHT (n=58) SHT (n=175)
HbA1c (%) 5.4 ± 0.4 5.5 ±0.3† 5.7 ±0.7
Fasting serum glucose
(mmol/l)
5.1 ± 0.5 5.3 ±0.9† 5.8 ±1.3
Elevated fasting glucose (%) 16.9 29.1† 49.4
Fasting serum insulin (pmol/l) 107.8 ± 150.5 134.9 ±110.5 133.9 ±179.5






625.3 ± 379.0 809.0 ±520.1* 762.6 ±446.2
Cholesterol (mmol/l) 5.4 ± 1.0 5.7 ±1.1 5.5 ±1.1
Triglycerides (mmol/l) 1.4 ± 1.0 1.7 ±1.1 1.7 ±1.2
Elevated triglycerides (%) 19.3 35.7 33.1
HDL cholesterol (mmol/l) 1.3 ± 0.3 1.2 ±0.3 1.3 ±0.3
LDL cholesterol (mmol/l) 3.5 ± 0.9 3.8 ±1.0 3.7 ±1.0
Serum creatinine (µmol/l) 70.5 ± 12.7 75.9 ±13.0* 73.1 ±13.2
eGFR (ml/min/1.73 m2) 94.6 ± 15.7 92.9 ±14.7 91.6 ±15.4
UACR (mmol/mg) 0.6 ± 0.4 0.8 ±1.2 2.3 ±14.0
eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-
density liopoprotein; HOMA-IR, homeostatic model assessment of insulin resis-
tance; LDL, low-density lipoprotein; MHT, masked hypertension; NT, normoten-
sion; SHT, sustained hypertension; UACR, urinary albumin–creatinine ratio.
*P<0.05 versus NT.
†P<0.05 versus SHT.
Table 4 Significant covariates of masked hypertension compared
with normotension and sustained hypertension patients in
univariable logistic regression analyses
Variables MHT vs. NT MHT vs. SHT
Age (years) 0.90 (0.86–0.94)†
Sex (male) 2.56 (1.29–5.09)†
Weight (kg) 1.02 (1.00–1.05)*
High-normal office BP 3.02 (1.47–6.20)†
Metabolic syndrome 3.77 (1.82–7.84)† 0.51 (0.27–0.94)*
HbA1c 0.40 (0.20–0.79)†
Fasting serum glucose (mmol/l) 0.59 (0.40–0.87)†
Elevated fasting glucose 0.42 (0.22–0.81)†
Diabetes 0.38 (0.16–0.90)*
Serum creatinine (µmol/l) 1.03 (1.01–1.06)*
Carotid plaque 0.17 (0.06–0.48)†
PWV (m/s) 0.76 (0.62–0.93)†
High PWV 5.18 (1.01–26.61)* 0.33 (0.13–0.81)*
BP, blood pressure; HbA1c, hemoglobin A1c; MHT, masked hypertension; NT,
normotension; PWV, pulse wave velocity; SHT, sustained hypertension.
*P<0.05.
†P<0.01.
Table 5 Covariates of masked hypertension compared with
normotension and sustained hypertension patients in multivariable
multinomial logistic regression analysis
MHT vs. NT MHT vs. SHT
OR (95% CI) P OR (95% CI) P
High PWV 1.28 (0.96–1.69) 0.086 0.79 (0.64–0.99) 0.043
Sex (male) 2.02 (0.97–4.20) 0.061 1.87 (0.97–3.60) 0.063
Carotid plaque 2.08 (0.76–5.56) 0.154 0.31 (0.13–0.75) 0.009
Diabetes 1.27 (0.34–4.76) 0.716 0.50 (0.19–1.31) 0.158
Metabolic syndrome 2.61 (1.05–6.45) 0.038 0.67 (0.31–1.42) 0.293
High-normal BP 2.31 (1.05–5.08) 0.038 1.34 (0.68–2.65) 0.395
BP, blood pressure; CI, confidence interval; MHT, masked hypertension; NT,
normotension; OR, odds ratio; PWV, pulse wave velocity; SHT, sustained
hypertension.
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in previous population-based studies [5,6,27–32]. Our
findings in an overweight and obese cohort add to this
knowledge by showing that specific clinical character-
istics, including the presence of metabolic syndrome and
high-normal office BP, may help to identify patients with
MHT at a time when clinical atherosclerosis is still not
detectable by cIMT and PWV.
In the present study, MHT patients had higher fasting
C-peptide compared with NT, reflecting higher endo-
genous insulin production [33], whereas the prevalence of
diabetes did not differ between MHT and NT groups.
Some previous studies have shown a gradual increase in
HOMA-IR from NT to MHT and SHT [29,31], but
HOMA-IR did not differ between the BP categories in
the present study. In the prospective Pressione Arteriose
Monitorate E Loro Associazioni study, a higher incidence
of diabetes was found in MHT patients compared with
NT patients during 10 years of follow-up [5]. Subclinical
arterial damage has been reported to be equally common
in MHT and SHT patients [34]. As shown in multi-
variable analysis, MHT was associated with nominally
higher PWV when adjusted for the presence of diabetes
and metabolic syndrome, possibly reflecting early arterial
dysfunction. In contrast, we found established athero-
sclerosis to be significantly less common in theMHT than
the SHT group, whether measured as increased aortic
stiffness by carotid–femoral PWV or by carotid plaques
from ultrasound. MHT has been suggested as a precursor
of SHT [6], and hence may represent an earlier stage of a
progressive disease, which in turn may explain the lower
prevalence of atherosclerosis found in patients with MHT
in the present study.
Study limitations
Our study has several potential limitations. Although the
standardized questionnaire to gather self-reported health
information was quality assured by the general practi-
tioner, health problems may have been under-reported.
There is a possibility of volunteer bias as the patients
included in the FATCOR study were recruited at a
medical center specialized in the management of over-
weight and obese patients, probably recruiting patients
more concerned about their health than unselected
overweight and obese patients. However, more than 50%
of SHT was diagnosed through study participation, as
was more than 20% of diabetes in the total study popu-
lation, pointing to the value of thorough cardiovascular
risk factor assessment in obese patients. The FATCOR
study included overweight and obese patients aged
30–65 years without known cardiovascular disease and
generalization of results to other populations should be
done with caution. Finally, because of the cross-sectional
design, it is not possible to infer causality of the asso-
ciations discovered in this study.
Conclusion
MHT was found in 17.1% of overweight and obese
patients without cardiovascular disease participating in
the FATCOR study, and in 39.2% of patients with nor-
mal office BP, pointing to the vast potential for a more
timely diagnosis of hypertension in such patients if
ambulatory BP recording is used more widely. Compared
with NT patients, MHT was particularly common in
patients with high-normal office BP or metabolic syn-
drome. Compared with SHT patients, MHT had sig-
nificantly lower prevalence of subclinical arterial damage.
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